Biopharma buyouts still pricey
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
Small Galapagos setback prompts a bigger loss of sentiment
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
SITC 2020 – embargo snafu triggers the first movers
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
J&J pause adds to adenovirus vaccine doubts
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Gilead rescues biopharma’s takeout scene
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
Boehringer hopes schizophrenia apps will Click into place
Licensing deal could enable bundling of antipsychotics with management technology.
Esmo 2020 preview – late-breaking immunotherapy
The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.
